IL1RL2 and psoriasis 14, pustular: Spesolimab, a monoclonal antibody targeting the IL-36 receptor, became the first targeted therapy specifically approved for GPP in 2022. The Effisayil-1 clinical trial demonstrated its rapid efficacy in alleviating acute GPP symptoms and significantly reducing disease severity [11].